PTC Therapeutics (PTCT) Expected to Announce Earnings on Thursday

Key Points

• PTC Therapeutics will report Q1 2026 results after the close on May 7, with analysts expecting EPS of -$0.475 and revenue of $219.63 million; the company’s earnings call is scheduled for 4:30 PM ET.
• The prior quarter was a significant miss—PTC reported EPS of - $1.67 versus a -$0.21 estimate and revenue of $164.68M versus $281.45M (down 22.7% year‑over‑year); analysts now model about -$1 EPS for the current fiscal year and $2 for the next.
• Shares trade around $64.55 with a market cap of $5.35B and a 52‑week range of $35.95–$87.50; analyst consensus is a “Moderate Buy” with an average target of $84.40, while insiders have sold roughly 126,492 shares (~$8.63M) in the past 90 days.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) is anticipated to release its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect PTC Therapeutics to post earnings of ($0.4750) per share and revenue of $219.6290 million for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The company had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. PTC Therapeutics's revenue for the quarter was down 22.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.85) earnings per share. On average, analysts expect PTC Therapeutics to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

PTC Therapeutics Price Performance

Shares of PTCT opened at $64.55 on Thursday. The company's 50-day moving average is $68.07 and its 200-day moving average is $72.08. The firm has a market capitalization of $5.35 billion, a PE ratio of 8.34 and a beta of 0.55. PTC Therapeutics has a fifty-two week low of $35.95 and a fifty-two week high of $87.50.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Truist Financial raised shares of PTC Therapeutics to a "strong-buy" rating in a report on Wednesday, March 25th. Wall Street Zen cut PTC Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, February 21st. Wells Fargo & Company decreased their target price on PTC Therapeutics from $93.00 to $86.00 and set an "overweight" rating on the stock in a research report on Friday, February 20th. Jefferies Financial Group lowered PTC Therapeutics from a "buy" rating to a "hold" rating and lowered their target price for the stock from $91.00 to $76.00 in a research note on Monday, March 30th. Finally, Bank of America dropped their price target on PTC Therapeutics from $97.00 to $93.00 and set a "buy" rating for the company in a report on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $84.40.

Insider Buying and Selling

In other news, VP Mark Elliott Boulding sold 3,081 shares of the business's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total value of $213,698.16. Following the completion of the transaction, the vice president directly owned 108,231 shares in the company, valued at approximately $7,506,902.16. The trade was a 2.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew B. Klein sold 7,371 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $511,252.56. Following the sale, the chief executive officer owned 387,082 shares in the company, valued at $26,848,007.52. This represents a 1.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 126,492 shares of company stock valued at $8,634,621 in the last ninety days. Insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On PTC Therapeutics

A number of institutional investors have recently modified their holdings of the business. IFP Advisors Inc boosted its stake in PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 310 shares in the last quarter. Virtus Investment Advisers LLC lifted its holdings in shares of PTC Therapeutics by 3.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 9,033 shares of the biopharmaceutical company's stock worth $686,000 after acquiring an additional 316 shares during the last quarter. UMB Bank n.a. acquired a new stake in shares of PTC Therapeutics in the 4th quarter valued at approximately $26,000. Mariner LLC grew its holdings in shares of PTC Therapeutics by 5.1% during the 3rd quarter. Mariner LLC now owns 8,745 shares of the biopharmaceutical company's stock valued at $537,000 after purchasing an additional 426 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of PTC Therapeutics by 96.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 921 shares of the biopharmaceutical company's stock valued at $70,000 after purchasing an additional 452 shares during the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.